The Project Grant award R01HL175924, totaling $664,824.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research by the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to define the cellular and molecular mechanisms underlying congenital aortic valve disease, a common form of pediatric heart disease, and to test new pharmacologic therapies to treat the condition and prevent disease progression. The overarching goal is to leverage a newly developed mouse model that recapitulates the human disease to elucidate key biological pathways involving the NOTCH1, GATA5, and NOS3 genes and evaluate potential mechanism-based therapeutic interventions. This multi-year project aims to advance the understanding and treatment of this significant cardiovascular health challenge.
Generated 1/28/25, 9:39 AM